GLP-2 peptide research covers intestinal growth, gut barrier function, and teduglutide analogs. Compare mechanisms, study models, and sourcing standards.
GLP-2 peptide research examines glucagon-like peptide-2, a 33-amino-acid hormone that intestinal L-cells release alongside GLP-1 after a meal. Its core job is trophic: it drives crypt cell proliferation, increases villus height, and expands the absorptive surface of the small intestine. Because of that role, most laboratory work centers on intestinal adaptation, gut barrier integrity, and the analogs engineered to survive longer in circulation.
What GLP-2 Is and How It Signals
GLP-2 is generated by cleavage of proglucagon in enteroendocrine L-cells of the distal ileum and colon. It binds the GLP-2 receptor (GLP-2R), a class B G-protein-coupled receptor found mainly on enteric neurons, subepithelial myofibroblasts, and enteroendocrine cells.
Receptor activation raises intracellular cAMP and triggers downstream signaling through IGF-1, ErbB ligands, and VEGF, which together promote epithelial proliferation and suppress apoptosis. Importantly, GLP-2R is not expressed on the intestinal epithelium itself, so the peptide works largely through indirect, paracrine routes.
Native GLP-2 has a half-life of only about 5 to 7 minutes because DPP-4 cleaves it near the N-terminus. That single fact explains why nearly every research-grade analog carries an N-terminal modification, most often a glycine-to-alanine or glycine-to-serine substitution.
Main Research Areas in GLP-2 Studies
Intestinal adaptation and mucosal growth
Preclinical models of short bowel syndrome, massive resection, and chemotherapy-induced mucositis are the workhorses here. Rodent studies consistently report increased crypt depth, villus height, and total mucosal DNA content after subcutaneous GLP-2 administration.
Barrier function and inflammation
Researchers measure tight-junction protein expression, transepithelial electrical resistance, and bacterial translocation to test whether GLP-2 tightens the gut barrier. Rodent colitis models show reduced inflammatory cytokines, though human inflammatory bowel disease trials have produced mixed results.
Motility, absorption, and bone
GLP-2 slows gastric emptying and intestinal transit, which extends nutrient contact time with the mucosa. A separate line of work links the peptide to reduced bone resorption and higher bone mineral density in animal models, an effect that appears independent of calcium intake.
GLP-2 Compared with Other Incretin-Family Peptides
Incretin peptides get conflated constantly in literature searches. The table below separates the main players and their dominant research focus.
| Peptide | Primary receptor | Dominant research focus | US regulatory status |
|---|---|---|---|
| GLP-1 (7-36) | GLP-1R | Glucose-dependent insulin secretion, appetite | Endogenous hormone; analogs approved |
| GLP-2 (1-33) | GLP-2R | Intestinal growth, barrier, absorption | Endogenous hormone; not a drug itself |
| Teduglutide | GLP-2R | Short bowel syndrome, intestinal rehabilitation | FDA-approved (Gattex) |
| Semaglutide | GLP-1R | Type 2 diabetes, obesity | FDA-approved |
| Tirzepatide | GIPR + GLP-1R | Dual incretin metabolic research | FDA-approved |
GLP-2 does not act meaningfully on the GLP-1 receptor, and GLP-1 does not drive intestinal growth. Assuming the two peptides are interchangeable is one of the most common ways researchers end up designing the wrong assay.
Naming Confusion: GLP-2, GLP-3, and Vendor Labels
GLP-3 is not a recognized endogenous hormone; the label circulates mainly through forums and product listings. Search interest in glp-3 research peptide most likely reflects confusion with GLP-1, GLP-2, or third-generation incretin analogs rather than a distinct signaling system. Always verify a compound against its amino acid sequence and CAS number instead of trusting a catalog name.
Study Design and Dosing Considerations
Most published rodent protocols use subcutaneous GLP-2 or a stable analog at roughly 0.05 to 0.5 mg/kg per day, often for 7 to 14 days, with crypt and villus histology as the primary endpoint. These are preclinical reference points, not human dosing guidance.
- Controls: saline versus analog versus a receptor antagonist such as GLP-2(3-33) gives the cleanest read on receptor-specific effects.
- Timing: the peak proliferative response typically appears 5 to 10 days after the first dose.
- Sample handling: native GLP-2 degrades quickly, so plasma assays require a DPP-4 inhibitor and cold processing.
- Readouts: crypt depth, villus height, Ki-67 or BrdU staining, TEER, and Lgr5+ stem cell markers are standard.
Sourcing Research-Grade GLP-2
Peptide quality varies enormously between suppliers, and a batch-specific certificate of analysis is the minimum acceptable documentation. Look for HPLC purity above 98%, mass spectrometry confirmation of the expected molecular weight (native GLP-2 is about 3,766 Da), and endotoxin testing if you plan cell-culture work.
Cold-chain shipping matters because lyophilized GLP-2 is hygroscopic and degrades faster once reconstituted. Store aliquots at -20 °C or below and avoid repeated freeze-thaw cycles.
When comparing catalogs, lot-level testing matters more than price per milligram. Many labs start with a small trial order from a peptide research supply vendor that publishes third-party analytics before committing to a bulk purchase. Others ask colleagues at a peptide research institute which lots have performed consistently in their hands.
The same purity standards apply across the incretin family. Listings for tirzepatide research peptide for sale often sit beside GLP-1 and GLP-2 items in the same catalog, so evaluate every compound on its own documentation. If you are looking for the best research peptide company for gut-focused work, prioritize vendors that post batch-specific HPLC and MS data rather than generic spec sheets.
Safety, Regulatory, and Ethical Context
Native GLP-2 is not FDA-approved for human use, and research-grade material is sold for laboratory purposes only. Its analog teduglutide carries a boxed warning for intestinal neoplasia, colorectal polyps, and fluid overload.
Any in vivo work requires institutional animal care and use committee approval, and questions about human use belong with a licensed healthcare professional. This article is educational and is not medical advice.
Frequently Asked Questions
What is GLP-2 and what does it do in the body?
GLP-2 is a 33-amino-acid hormone released by intestinal L-cells after a meal. Its primary role is trophic: it promotes crypt cell proliferation, increases villus height, and slows transit so the gut absorbs more nutrients. It signals through the GLP-2 receptor, which is not expressed on the intestinal epithelium itself.
Is GLP-2 approved for human use in the United States?
Native GLP-2 is not an approved drug. Its longer-acting analog teduglutide (Gattex) is FDA-approved for short bowel syndrome in adults and some pediatric patients, and it carries a boxed warning for intestinal neoplasia and fluid overload. Research-grade GLP-2 sold online is labeled for laboratory use only.
How should GLP-2 peptide be stored and handled in the lab?
Store lyophilized GLP-2 at -20 °C or lower, protected from light and moisture. Once reconstituted, keep aliquots cold and avoid repeated freeze-thaw cycles. Because native GLP-2 has a half-life of only about 5 to 7 minutes, plasma assays need a DPP-4 inhibitor and rapid cold processing.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.